Myriad Genetics has seen its price target nudged higher even as the core fair value estimate stays flat at about $8.52 per share, reflecting a cautious acknowledgment of recent operational progress.

Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its ...

Capricorn sun guides Sampath Raj’s steady career rise, discipline and loyal relationships, with practical guidance for ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...

Discover why iShares Core Dividend Growth ETF (DGRO) is a strong buy for consistent dividend growth. Click here to read my ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This dual-therapy targets a pathway ...

Cervical cancer is the fourth most common cancer for women in the world, with more than 660,000 new cases and nearly 350,000 deaths per year. Now, University of Maryland mathematicians have developed ...

The Cure's Robert Smith has announced the line-up for the Teenage Cancer Trust at the Royal Albert Hall concert series 2026. The unique week of events at London's greatest concert hall will take place ...

The Union Ministry of Health & Family Welfare convened a two-day National Workshop on Strengthening Cancer Care and Urban Health on 27–28 November 2025 at Sushma Swaraj Bhawan, New Delhi. The ...